Home > News > Headline News


Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast ...

October 8, 2015

By FDA Today

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer

Breast cancer and mammograms: Study suggests ‘widespread overdiagnosis’

September 2, 2015

By The Washington Post

As expected, the researchers found that the number of breast cancer diagnoses rose with more aggressive screenings. The surprise: the number of deaths remained the same.

Is ER the new HER2 (which used to be the new ER)? Drs Lisa Carey and Eric Winer elaborate

September 2, 2015

By Neil Love, MD

To sort out what this development and others in the management of ER-positive breast cancer mean to daily patient care and clinical research I sat down with Drs Lisa Carey and Eric Winer, and this, the first of 2 programs developed from that conversation, provides an array of video highlights focused on palbo, other CDK inhibitors and the remarkable evolution of genomic assays in the selection of systemic therapy for patients with localized ER-positive, HER2-negative disease. The video comments are available with a quick click and are summarized below.

Combination PANVAC, Docetaxel May Provide Benefit in Breast Cancer

August 24, 2015

By Cancer Therapy Advisor

Results from an open-label phase 2 randomized clinical trial suggested that the combination of PANVAC and docetaxel in metastatic breast cancer may provide clinical benefit, according to an article published online ahead of print in JAMA Oncology.

Her Cancer Cells Were to Be Immortalized; What Happened?

August 21, 2015

By Medscape

One year ago, Loyola University in Chicago announced the initiation of a project to "immortalize" the tumor cells of a woman with an especially aggressive breast cancer.

Molecular Imaging May Help Tailor Breast Cancer Therapies

August 13, 2015

By OncLive Gina Battaglia, PhD

Although many drugs are under study for patients with metastatic breast cancer, there is a pressing need to establish methods of predicting response and improving drug delivery, and researchers are looking toward molecular imaging techniques to help reach those goals, according to Pamela Munster, MD, a specialist in developmental therapies.

HOW TO HELP: Fundraiser for Easton school psychologist facing breast cancer

August 1, 2015

By Rebecca Hyman, easton.wickedlocal.com

Barbara Bigelow and her husband Tim walked into a jewelry store in Wickford, R.I. recently and were both drawn to the same Indian amulet.

    The silver pendant is decorated with an image of Durga, the warrior goddess, riding her tiger. She is strong and beautiful and full of rage, Barbara Bigelow said.

    Tim Bigelow bought it for his wife immediately.

    She has stage IV metastatic breast cancer. The average life expectancy for someone with her condition is 26 months, she said. Bigelow says she plans to fight until the end even though it is a battle she does not expect to win.

    She will fight not because she is afraid of death, but because she loves life, she said.

    Barbara Bigelow is a warrior.

Why She Matters So Much: I hold tight to the belief that I am a survivor who is living with, not dying from, metastatic bc

July 16, 2015

By PAULA VINCENT, RN, CNM , Cure Magazine

IT’S HARD TO FIND a silver lining when you’ve been told you have cancer for the second time. This is my life now. I hold tight to the belief that I am a survivor who is living with, not dying from, metastatic breast cancer. This helps provide the balance, hope and gratitude I try to find in every moment and with each person who is a part of my life and recovery.

Within a short time after starting treatment, I realized the “fit” wasn’t right with both the oncologist I had been assigned to and the oncology nurse that had been caring for me. I knew this time around that I needed to be both mentally and physically prepared for the hardest battle I had ever fought, and l knew with even more certainty I needed a team of warriors who would always be by my side throughout treatments that would never finish.


MET-UP: new metastatic breast cancer protest group launches

July 16, 2015

By Nick Mulcahy, Medscape Medical News

The pink culture of breast cancer is about to get an infusion of red hot.

A small but growing group of women with metastatic breast cancer and their supporters have formed MET UP, an activist group modelled on the confrontational AIDS Coalition to Unleash Power (ACT UP) and sharing the same inspiration of anger, rebellion, and fellowship/sisterhood.

"MET UP is…committed to direct action for a viable cure for breast cancer. We protest and demonstrate," reads a portion of the group's mission statement, which was recently posted online.

Fred Hutchinson Cancer Center receives $4.1 M grant to study ways to prevent metastatic breast cancer.

June 30, 2015

By Fred Hutchinson Cancer Center, Seattle: press release

Cyrus Ghajar, Ph.D., a metastatic breast cancer researcher at Fred Hutchinson Cancer Research Center, has received a $4.1 million Department of Defense Breast Cancer Research Program (BCRP) “Era of Hope” Scholar Award.

Ghajar is investigating two different paths for dealing with these dormant disseminated tumor cells: keeping them asleep and inactive, or destroying them altogether.

“Basically, we are hedging our bets. You might be able to keep these cells asleep forever, but this carries an inherent risk because you are leaving these ticking time bombs in your body. Perhaps we can mitigate this with a strong enough ‘sedative,’” he said. “But just in case, we also have ways we think will allow us to specifically get rid of them.”

According to Ghajar, the phenomenon of tumor dormancy has not been the subject of much study over the years. As a result, “we don’t really know a whole lot about these cells in terms of what puts them to sleep and what wakes them up,” he said.

‹ First  < 3 4 5 6 7 >  Last ›